💉

GHRP-6

GHRP-6 is a synthetic peptide that tells your pituitary to release a pulse of growth hormone. It was the first compound in this class, synthesised by Cyril Bowers in 1984, and it was the molecule that eventually led to the discovery of ghrelin itself. Today it's used the same way
💉
Ipamorelin
and
💉
GHRP-2
are, to push GH and IGF-1 higher for deeper sleep, faster recovery, gradual body composition changes, and better connective tissue.
The thing that sets GHRP-6 apart from its successors is the appetite effect. It makes you genuinely, sometimes uncomfortably, hungry within 20-30 minutes of injecting. That's why it largely fell out of favour once ipamorelin came along, and why almost everyone reaching for a GHRP today picks ipamorelin instead. If you're hearing about GHRP-6 specifically, it's usually for one of two reasons: someone is bulking hard and wants the hunger as a feature, or it's the cheapest GHRP on the grey market and people use it as a budget GH protocol. Almost always stacked with a GHRH analogue like
💉
CJC-1295
no-DAC for the synergy.

Deep-dive

GH is released in pulses from the anterior pituitary under two opposing controls, GHRH (the gas pedal) and somatostatin (the brake), with ghrelin acting as a third input that amplifies the GHRH signal. GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that binds the ghrelin receptor (GHSR-1a) on pituitary somatotrophs and triggers a GH pulse the same way endogenous ghrelin does. The released GH then drives IGF-1 production in the liver and peripheral tissues, and IGF-1 mediates most of the anabolic, lipolytic, and tissue-repair effects people are actually after.
The historical note matters. GHRP-6 came before the discovery of ghrelin. Bowers and Momany published the original synthesis in 1984, showing the hexapeptide produced dose-dependent GH release in vitro and in vivo through a pathway entirely distinct from GHRH. Bowers spent the next 15 years arguing the body must have its own endogenous version of this molecule. Most colleagues dismissed the claim until ghrelin was identified in 1999, at which point GHRP-6 was retrospectively understood as a ghrelin-receptor agonist. The entire GHRP class, ipamorelin, hexarelin, GHRP-2, MK-677, was built on the scaffold of this one peptide.
Pharmacokinetics. GHRP-6 has a plasma half-life of around 2.5 hours and produces a GH pulse that peaks at 15-60 minutes after subcutaneous or intravenous administration and returns to baseline by 2-3 hours. Oral bioavailability is under 1%, intranasal absorption is roughly 0.3-1% of the subcutaneous dose, which is why subcutaneous injection is the practical route. One injection produces one clean pulse and clears. Dosing 2-3 times daily recreates discrete pulses rather than maintaining background elevation.
Potency and selectivity. GHRP-6 is potent on raw GH output but the least selective of the GHRPs. Bowers' 1990 study in 18 normal men established the human dose-response curve and showed that 1 mcg/kg IV produced peak GH levels of around 69 mcg/L, more than 50x baseline. It also showed that GHRP-6 plus GHRH produced GH release synergistically rather than additively, the foundation of every modern GHRP + GHRH stack. The trade-off, visible in that same paper, is that prolactin and cortisol rose about 2-fold above baseline at the 1 mcg/kg dose. Raun's 1998 swine comparison confirmed this directly: GHRP-6 released GH with similar potency to ipamorelin but also elevated ACTH and cortisol at GH-releasing doses, while ipamorelin did not. GHRP-6 also has more pronounced effects on ghrelin's other pathways (appetite, gastric motility) than the more selective successors.
Appetite is the defining feature. This is the single biggest separator between GHRP-6 and every other compound in its class. GHRP-6 reliably produces strong, sometimes uncomfortable hunger within 20-30 minutes of injection, more pronounced than GHRP-2 and dramatically more than ipamorelin. The mechanism is direct: GHRP-6 activates the ghrelin receptor in the hypothalamic arcuate nucleus, which drives NPY/AgRP neurons and increases food intake. Wren's 2001 study demonstrated that central GHRP-6 in rats produced food intake increases independent of the GH effect and activated the same appetite-regulating brain regions that endogenous ghrelin does. Practically, this means GHRP-6 is the GHRP of choice if you want hunger (bulking, recovery from cachexia, building back muscle in older adults with poor appetite) and the GHRP to avoid if you don't (fat loss phases, anyone with disordered eating history).
Cardioprotective signal. This is the more interesting and less-discussed angle on GHRP-6. The Berlanga group at the Cuban Centre for Genetic Engineering has spent two decades documenting cytoprotective and cardioprotective effects of GHRP-6 that appear to be independent of the GH/IGF-1 axis, mediated instead through the CD36 receptor on cardiomyocytes. Their 2007 paper showed that GHRP-6 administration reduced infarct size by over 70% in a porcine model of acute myocardial infarction by preserving antioxidant defences and reducing reactive oxygen species. Follow-up work in 2024 showed GHRP-6 prevented doxorubicin-induced cardiomyopathy in rats by activating pro-survival pathways. These are animal data, not human trials, but the mechanism is plausible and the effect sizes are large. A patent has been filed for GHRP-6 as a late cardioprotective agent for post-MI use. None of this is approved in humans, but it explains why GHRP-6 keeps coming up in the cardioprotective peptide conversation.
Tolerance and desensitisation. Huhn's 1993 study infused GHRP-6 continuously for 24 hours in normal men and found that the GH response to a subsequent GHRP-6 bolus was specifically attenuated, while the response to GHRH was preserved. The receptor desensitises with sustained exposure, which is the mechanistic argument for pulsatile rather than continuous dosing and for cycling. Daily injection protocols don't run into this at the same rate as continuous infusion but the principle still applies, sustained daily use erodes the response over weeks to months.
Human clinical data is moderate but indirect. GHRP-6 has more accumulated human data than ipamorelin, simply because it's been around since 1984. The data covers pharmacokinetics, GH response in healthy volunteers, response in GH-deficient children and adults, response in older adults with age-related GH decline, and acute appetite effects. There are no large long-term randomised trials measuring body composition, lean mass, fat mass, sleep architecture, or skin metrics as endpoints in healthy adults. The cardioprotective work is preclinical. As with the rest of the GHRP class, popularity in the peptide world is driven by extrapolation from GH/IGF-1 biology, animal data, and consistent user reports.
Anecdotal pattern. The most consistently reported effect, usually within the first hour of the first injection, is intense hunger, often described as the most reliable potency check across the entire GHRP class. If you inject GHRP-6 and aren't ravenous within 30-45 minutes, the product is almost certainly underdosed or mislabelled. Deeper sleep and more vivid dreams typically follow in the first 1-2 weeks. Faster recovery from training tends to show up within the first month. Over 1-3 months people report improved skin firmness and hydration, easier muscle gain when calories are pushed, and faster healing of nagging soft-tissue issues. Less consistent: fat loss (the hunger usually washes this out), large strength changes, libido changes. Common complaints: facial flushing in the 30-60 minutes after injection (more pronounced than with ipamorelin), mild water retention, tingling or numbness in hands at higher doses, occasional lethargy if dosed too late in the day, and a stronger cortisol-like edge (mild anxiety, restlessness) than the more selective GHRPs.
Women. GH and IGF-1 biology is broadly similar between sexes but women have higher baseline GH pulse amplitude and a more pronounced response to oestrogen, which upregulates GH secretion. Most GHRP-6 clinical work has enrolled both sexes, and women generally show comparable GH and IGF-1 responses to the same weight-adjusted doses. Practically, women tend to use the same or slightly lower dose range as men and report similar effects on sleep, recovery, hunger, and skin. The appetite effect is reported equivalently or sometimes more strongly in women. Perimenopausal and postmenopausal women may notice more benefit because endogenous GH output declines alongside oestrogen, which leaves more room for an evoked pulse to register. The strong appetite effect deserves more attention in women, both because disordered eating patterns are more prevalent in this population and because the practical consequences of a hunger spike are easy to underestimate before you've felt it. Skip GHRP-6 in pregnancy and breastfeeding, the GH/IGF-1 axis is tightly regulated during these periods and there's no safety data.
Older adults. GH output declines roughly 14% per decade after age 30. GHRP-6 produces a robust GH and IGF-1 response in older adults whose endogenous output has declined, and the appetite effect can be useful in older adults with sarcopenia or poor intake. Older studies in adults over 60 showed continuous GHRP-6 infusion sustained IGF-1 elevation over weeks. The cardioprotective signal, if it translates to humans, would also be most relevant in this group. Long-term safety in older adults is the weakest part of the evidence base, see the risks section.
Limitations of the evidence. Solid pharmacokinetic data going back four decades, solid acute pharmacodynamics in humans, decent short-term clinical data in GH-deficient children and older adults, no long-term randomised body composition trials in healthy adults. The cardioprotective work is preclinical only. Tolerance develops with sustained continuous exposure. The compound is widely sold as a research chemical from grey-market suppliers, product purity and identity vary, and it has no approved human therapeutic indication in any major jurisdiction. The FDA placed GHRP-6 on the 503A Category 2 bulks list in 2023 alongside the other GH-releasing peptides, citing immunogenicity and impurity concerns.

Dosage:

  • Standalone GHRP-6: 100-300 mcg subcutaneous, 2-3x daily. Most common single dose is 100-150 mcg pre-bed. The pituitary saturates around 300 mcg per pulse, going higher doesn't produce more GH, just more side effects (water retention, tingling, stronger hunger surge, stronger cortisol edge)
  • CJC-1295 (no-DAC) + GHRP-6 stack: 100 mcg of each, taken together in the same syringe, 2-3x daily. Pre-bed is the priority dose, pre-workout is next, and a morning dose rounds out a full protocol. This stack is the default if you've chosen GHRP-6 over ipamorelin
  • Timing: Inject on an empty stomach, 30-60 minutes before food. Elevated insulin and amino acids from a meal blunt the GH pulse via feedback at the pituitary. The 20-30 minute hunger surge actually times well with eating windows, inject, wait 20 minutes, eat. Pre-bed dosing aligns with the natural nighttime GH surge during deep sleep and is the most effective single dose
  • Frequency over dose. The pituitary saturates around 300 mcg per pulse. 3 daily injections at 100 mcg outperform one daily injection at 300 mcg for sustained effect, and 100 mcg keeps the cortisol and prolactin bump minimal where 300 mcg makes it more noticeable
  • Cycling: Most protocols run 8-12 weeks on, then 4-6 weeks off. The off period lets pituitary sensitivity reset and gives you a window to recheck IGF-1, fasting glucose, and HbA1c. The shorter cycles versus ipamorelin reflect the receptor desensitisation evidence and the cortisol/prolactin cost of sustained use
  • Women: Same dose range as men, often starting at 100 mcg per injection and adjusting over 4-6 weeks. Perimenopausal and postmenopausal women may notice effects faster because endogenous GH baseline is lower. The appetite effect is at least as strong in women, factor this into the bulking/cutting decision
  • Reconstitution: Comes as lyophilised powder, reconstitute with bacteriostatic water, store refrigerated, use within 30 days. Subcutaneous injection into abdominal fat or thigh with an insulin syringe. Rotate sites
  • Stacks: The standard pairing is CJC-1295 no-DAC for the synergy. Some run alongside
    BPC-157
    BPC-157
    for tissue repair during injury cycles. Stacking with exogenous HGH is redundant and shuts down the natural pulse. Don't combine with ipamorelin or GHRP-2, they target the same receptor and you just get more side effects without more GH

Here's what you can expect:

The first and most reliable signal, usually within the first 30-60 minutes of the first injection, is hunger. Sharp, sometimes uncomfortable, often described by users as a switch flipping on. This is the most consistent potency check for GHRP-6 across forums and clinics, no hunger means the product is almost certainly underdosed or mislabelled. Deeper sleep and more vivid dreams follow in the first 1-2 weeks. Faster recovery between training sessions shows up within the first month. Skin firmness and hydration improvements come gradually over 2-3 months, similar to
GHK-Cu
GHK-Cu
but driven by IGF-1 rather than direct fibroblast signalling. Body composition changes (modest visceral fat reduction, lean mass gain) build over 3-6 months and require that you're training and eating in line with your goal, the strong appetite effect means GHRP-6 works with bulking and works against cutting.
Mild facial flushing and warmth in the 30-60 minutes after injection is common and usually fades after the first few doses. A mild cortisol-like edge (slight restlessness, mild anxiety, modest water retention) is possible at the higher end of the dose range.

Side effects & risks:

  • Strong appetite stimulation. The most universal and dose-dependent effect, and the primary reason GHRP-6 is no longer the default GHRP. Useful if bulking, a significant problem if not
  • Cortisol and prolactin elevation. More pronounced than with GHRP-2 and far more than with ipamorelin. Around 2-fold above baseline at the 1 mcg/kg human dose. Can manifest as anxiety, mild water retention, mood changes, and at the upper end gynaecomastia symptoms
  • Injection site reactions: mild redness, itching, occasional bruising. Rotate sites
  • Facial flushing and warmth in the first 30-60 minutes after injection. Vasodilatory effect, harmless, usually fades after the first few doses
  • Headache, lethargy, brain fog at higher doses or if dosed too late in the day. Pull the dose back
  • Water retention and tingling (paraesthesia) in hands and feet at the upper end of the dose range. Early sign of carpal tunnel-type symptoms from elevated GH/IGF-1. Reversible. Reduce dose
  • Insulin resistance and elevated fasting glucose. GH is counter-regulatory to insulin and sustained elevation pushes fasting glucose and HbA1c up. Most people see modest changes but meaningful if you already have prediabetes or metabolic syndrome. Recheck at 3 months
  • Receptor desensitisation. The Huhn 1993 data showed sustained continuous exposure attenuates the GH response. The reason most protocols cycle on the shorter end (8-12 weeks)
  • Active or recent cancer, avoid. IGF-1 is mitogenic and elevated IGF-1 is epidemiologically associated with increased risk of several cancers (colorectal, prostate, breast) over long timescales. Hard contraindication if you have a current or recent cancer diagnosis
  • Diabetic retinopathy can worsen with elevated GH/IGF-1. Avoid if you have any active diabetic eye disease
  • Sleep apnoea can worsen with GH elevation due to soft tissue changes, monitor if you have it
  • Pregnancy and breastfeeding: avoid
  • Pituitary tumour or unexplained hyperprolactinaemia: avoid until worked up. GHRP-6's prolactin elevation matters more in this context
  • Disordered eating history: the appetite effect is a hard reason to choose a more selective GHRP (ipamorelin) instead
  • Long-term safety data is essentially absent in healthy adults. Most human data is short-term (days to weeks) or in specific patient populations. Beyond 8-12 week cycles in healthy adults, you're inferring safety from related GH literature
  • Grey-market sourcing. Most GHRP-6 sold outside of research supply is labelled "research use only" and isn't made under pharmaceutical conditions. Identity, purity, and dose accuracy vary widely. The strong hunger effect is a useful built-in potency check, no hunger means the product is likely underdosed or wrong
  • Regulatory status: sits on the FDA 503A Category 2 bulks list. WADA prohibits it in and out of competition. No approved human therapeutic indication in the US, EU, or most jurisdictions

🩸

Blood markers

IGF-1, baseline and at 6-8 weeks. The most useful single marker for whether the compound is working and at what intensity. Aim for the upper end of the age-adjusted reference range, not above it.
Fasting glucose and HbA1c, baseline and at 3 months. The metabolic cost of sustained GH elevation. If fasting glucose creeps above 100 mg/dL or HbA1c above 5.7%, reduce dose or stop.
Fasting insulin and HOMA-IR, baseline if you want a more sensitive read on insulin resistance than glucose alone. Recheck at 3 months.
Prolactin and cortisol, baseline and at 6-8 weeks. More important here than for ipamorelin or GHRP-2 because GHRP-6 elevates both more reliably. Useful if you notice mood, anxiety, or water retention changes.
Full lipid panel, baseline. Recheck at 3 months. GH and IGF-1 can shift lipid markers in either direction.
TSH, free T4, free T3, baseline. GH can suppress TSH and shift T4 to T3 conversion. Worth knowing if you have thyroid history.
For most people the practical minimum is IGF-1 + fasting glucose + HbA1c at baseline and at 3 months, plus prolactin and cortisol if you're noticing mood or fluid retention changes. Everything else is for completeness or troubleshooting.

Related compounds without dedicated pages yet:
Hexarelin (examorelin)
No dedicated page yet, worth adding.
MK-677 (Ibutamoren)
No dedicated page yet, worth adding.
HGH (recombinant somatropin)
No dedicated page yet, worth adding.
Sold as a research chemical, not approved for human therapeutic use in the US, EU, or most jurisdictions.